Why the study?
Despite decreased use and improved monitoring, digoxin toxicity remains a significant cause of morbidity and mortality requiring maintained clinical suspicion and familiarity with treatment.
Highlights the importance of recognizing digoxin toxicity in the setting of acute renal failure and managing it with supportive care and digoxin-specific antibody fragments.
Ongoing digoxin toxicity risk warrants clinical vigilance; hypothesis-generating and should not yet change practice.
Since the publication of the Digitalis Investigation Group trial in 1997, digoxin use has declined significantly. Medications such as angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) and beta-blockers that have been demonstrated to have a decrease in morbidity and mortality are prescribed in favor of digoxin. Despite the reduction in digoxin use and improved therapeutic monitoring, digoxin toxicity remains a significant cause of morbidity and mortality. When digoxin toxicity is suspected, patients should be managed with supportive care, including discontinuation of the medication, and consideration for administration of digoxin-specific antibody fragment. We present a case of digoxin toxicity precipitated by acute renal failure, with a discussion on the pathophysiology and diagnosis of digoxin toxicity, along with the indications for administration of digoxin-specific antibody fragments. While digoxin toxicity is prescribed less commonly, physicians need to maintain a high index of suspicion and be comfortable with administering digoxin-specific antibody fragment in these scenarios.
No takes yet. Share an insight, caveat, or question.
Digiovanni-Kinsley et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: